With the news that the Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have authorized the Pfizer-BioNTech COVID-19 vaccine for those ages 5-11, we have received inquiries about the advisability of proceeding with vaccination in this age group. We fully agree with the CDC recommendation that everyone ages 5 and older get a COVID-19 vaccine to help protect against COVID-19. This includes individuals with celiac disease.
Although the risk of severe COVID-19 is far lower in children as compared to adults, widespread transmission of this virus, particularly since the development of the Delta variant, has resulted in thousands of hospitalizations and hundreds of deaths among children in the United States. Vaccination in this age group has been shown to be highly safe and effective, and is the strongest tool we have to prevent transmission and severe illness. To date, there is no evidence to suggest that people with celiac disease are at higher risk of severe COVID-19 or of the vaccine having a different safety or effectiveness profile in people with celiac disease. Additionally, there is no gluten in any of the authorized COVID-19 vaccines. Patients with concerns about vaccination and their particular circumstance should speak with their health care provider. We urge the public to proceed with COVID-19 vaccination promptly.
This study concludes that the frequency of celiac disease in children and its association with type 1 diabetes mellitus has increased during the COVID-19 pandemic.
This study examined how bread wheat got its gluten. Dr Kumar Gaurav said, "The discovery of this previously unknown contribution to the bread wheat genome is akin to discovering the introgression of Neanderthal DNA into the out of Africa human genome,"
"It is most likely to have occurred though a hybridization outside the Fertile Crescent. This group of Georgian accessions form a distinct lineage that contributed to the wheat genome by leaving a footprint in the DNA."
Research presented at the American College of Gastroenterology Annual Meeting last month showed adherence to a gluten-free diet may lead to an increased risk of non-alcoholic fatty liver disease.
This study found that patients with type 1 diabetes mellitus are more likely to have celiac disease than the general population.
This study looked to understand disease-specific and non-specific factors predicting disordered eating in adults with celiac disease.
Mozart Therapeutics has secured $55 million to study celiac disease and other immune-related conditions.
This study, based in the UK, hopes to provide guidelines to stream diagnosis by identifying who should be screened.